Clinical Trial

IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A single-center, Phase 1, open-label, investigator-initiated clinical trial evaluating the safety, tolerability, and preliminary efficacy of sarilumab (anti-IL-6R) monotherapy as a rescue in adult patients with belumosudil-refractory chronic graft-versus-host disease (cGVHD).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-17.
Trial Details
NCT Number NCT07484113
Lead Sponsor Stanford University
Conditions cGVHD
Enrollment 10 participants
Start Date 2026-09
Primary Completion 2028-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-12